Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in SRPT — Sarepta Therapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to SRPT Full portfolio

Position in SRPT

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$14,191,197
+$11,636,063 QoQ
Shares Held
652,169
+449.3% QoQ
Ownership
0.618%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in SRPT Over Time

Shares Held

Position Value (USD)

Derivatives in SRPT

reported options exposure · as of Mar 31, 2026
CallValue
$28,390,272
CallShares
1,304,700
PutValue
$7,063,296
PutShares
324,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. SRPT ranks #78 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in SRPT

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $28,390,272 1,304,700
2026-03-31 $14,191,197 652,169
2026-03-31 $7,063,296 324,600
2025-12-31 $10,869,752 505,100
2025-12-31 $9,415,000 437,500
2025-12-31 $2,555,134 118,733
2025-09-30 $9,875,431 512,477
2025-09-30 $12,860,798 667,400
2025-09-30 $11,766,262 610,600
2025-06-30 $5,166,867 302,156
2025-06-30 $6,380,010 373,100
2025-06-30 $5,648,130 330,300
2025-03-31 $8,653,992 135,600
2025-03-31 $7,230,806 113,300
2025-03-31 $15,047,989 235,788
2024-12-31 $18,287,136 150,400
2024-12-31 $75,120,855 617,821
2024-12-31 $15,539,202 127,800
2024-09-30 $20,931,564 167,600
2024-09-30 $38,466,120 308,000
2024-09-30 $115,675,490 926,219
2024-06-30 $122,579,718 775,821
2024-06-30 $61,003,800 386,100
2024-06-30 $31,947,600 202,200
2024-03-31 $42,864,206 331,100
2024-03-31 $197,177,547 1,523,077
2024-03-31 $36,132,286 279,100
2023-12-31 $129,479,453 1,342,730
2023-12-31 $50,567,892 524,400
2023-12-31 $38,263,424 396,800
2023-09-30 $148,855,007 1,227,974
2023-09-30 $37,578,200 310,000
2023-09-30 $49,954,762 412,100
2023-06-30 $24,931,004 217,700
2023-06-30 $102,004,452 890,713
2023-06-30 $31,618,972 276,100
2023-03-31 $34,928,051 253,414
2023-03-31 $35,243,131 255,700
2023-03-31 $66,571,890 483,000
2022-12-31 $15,614,390 120,500
2022-12-31 $52,542,227 405,481
2022-12-31 $44,160,864 340,800
2022-09-30 $11,288,565 102,122
2022-09-30 $9,020,064 81,600
2022-09-30 $37,008,792 334,800
2022-06-30 $42,976,291 573,323
2022-06-30 $4,759,960 63,500
2022-06-30 $10,396,952 138,700
2022-03-31 $46,503,897 595,288
2022-03-31 $11,647,692 149,100

Report a Problem

Category
Description
Email (optional, for follow-up)